With 80% Ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Boasts of Strong Institutional Backing
Yahoo FinanceApr 22 08:04 ET
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6,
GlobeNewswireApr 22 07:00 ET
FYBR, BCRX and SABR Are Among After Hour Movers
Seeking AlphaApr 18 16:56 ET
Express News | BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years
Moomoo 24/7Apr 17 04:36 ET
Express News | BioCryst Announces Approval of Orladeyo® (Berotralstat) by the Brazilian Health Regulatory Agency
Moomoo 24/7Apr 17 04:30 ET
Express News | Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
Moomoo 24/7Apr 10 07:10 ET
BioCryst Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 147.42% Needham → $12 Reiterates Buy → Buy 01/08/2024 147.42% Needham → $12 Reiterates Buy → Bu
BenzingaApr 10 07:08 ET
Why Investors Shouldn't Be Surprised By BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/S
With a price-to-sales (or "P/S") ratio of 2.9x BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in t
Simply Wall StApr 8 13:31 ET
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune &
GlobeNewswireMar 25 16:01 ET
13 Best Biotech Stocks To Buy Under $20
Yahoo FinanceMar 13 07:07 ET
Institutional Owners May Take Dramatic Actions as BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Recent 5.0% Drop Adds to One-year Losses
Key Insights Given the large stake in the stock by institutions, BioCryst Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 13 investors have a majority stake in
Simply Wall StMar 13 07:01 ET
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired
GlobeNewswireMar 5 07:01 ET
New Regulation Risk for BioCryst Pharmaceuticals – What's the Latest?
TipRanksFeb 29 01:00 ET
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript
Yahoo FinanceFeb 28 10:47 ET
BioCryst Pharmaceuticals Files for a Mixed Securities Shelf
Seeking AlphaFeb 27 17:15 ET
BioCryst Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations
Yahoo FinanceFeb 27 05:07 ET
Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call
Yahoo FinanceFeb 27 04:05 ET
What's Going On With BioCryst Stock After Earnings?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares are flat Monday after the company reported its fourth-quarter financial results before the opening bell.The Details:BioCryst reported quarterly loss
BenzingaFeb 26 13:30 ET
10 Health Care Stocks With Whale Alerts In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
BenzingaFeb 26 12:35 ET
Earnings Call Summary | BioCryst Pharmaceuticals(BCRX.US) Q4 2023 Earnings Conference
The following is a summary of the BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript:Financial Performance:BioCryst Pharmaceuticals reported a total revenue of $326 million in 2023
moomoo AIFeb 26 11:58 ET · Conference Call
No Data
No Data